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By binding growth factors (GFs), the ECM tightly regulates their
activity. We recently reported that the heparin-binding domain II of
ﬁbronectin acts as a promiscuous high-afﬁnity GF-binding domain.
Herewe hypothesized that ﬁbrin, the provisional ECM during tissue
repair, also could be highly promiscuous in its GF-binding capacity.
Usingmultiple afﬁnity-based assays,we found thatﬁbrin(ogen) and
its heparin-binding domain bind several GFs from the PDGF/VEGF
and FGF families and some GFs from the TGF-β and neurotrophin
families. Overall, we identiﬁed 15 unique binding interactions. The
GF binding ability ofﬁbrinogen caused prolonged retentionofmany
of the identiﬁed GFs within ﬁbrin. Thus, based on the promiscuous
and high-afﬁnity interactions in ﬁbrin, GF binding may be one of
ﬁbrin’s main physiological functions, and these interactions may
potentially play an importantandubiquitous roleduring tissue repair.
To prove this role in a gain-of-function model, we incorporated the
heparin-binding domain of ﬁbrin into a synthetic ﬁbrin-mimetic ma-
trix. In vivo, themultifunctional syntheticmatrix could fullymimic the
effect ofﬁbrin in a diabetic mousemodel of impairedwound healing,
demonstrating the beneﬁts of generating a hybrid biomaterial con-
sisting of a synthetic polymeric scaffold and recombinant bioactive
ECMdomains. The reproduction ofGF–ECM interactionswith aﬁbrin-
mimetic matrix could be clinically useful, and has the signiﬁcant ben-
eﬁt of amore straightforward regulatory path associatedwith chem-
ical synthesis rather than human sourcing.
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An important function of the ECM in tissuemorphogenesis andrepair is sequestration of growth factors (GFs), which control
multiple cellular processes. Interactions of GFs and the ECM
modulate the partitioning of GFs from the ECM to the soluble
phase and thus control their local concentration, diffusion, and
signaling (1, 2). For example, many GFs are able to bind the pro-
teoglycan components of the ECM (2). Moreover, it has recently
become more evident that ECM proteins such as ﬁbronectin and
vitronectin, which do not contain highly negatively charged sugar
chains, bind several GFs (3–8). In addition to sequestration of GF
by ECM components, the ECM also can modulate cosignaling
between adhesion and GF receptor systems. For example, we re-
cently showed that ﬁbronectin domains mediate synergistic sig-
naling between the receptors for VEGF-A, PDGF-BB, and bone
morphogenetic protein (BMP)-2 with the integrin α5β1 (9).
Hemostasis in wound healing is achieved initially by the for-
mation of a ﬁbrin clot through the conversion of circulating ﬁ-
brinogen into a ﬁbrin matrix during blood coagulation (10). Fibrin
serves as a provisional ECM for inﬁltrating cells, and thematrix has
been suggested to act as a reservoir for secreted GFs (11). Fibrin
(ogen) is known to have speciﬁc interactions with FGF-2, VEGF-
A165, and insulin-like growth factor binding protein (IGFBP)-3
(12–14). We recently reported that ﬁbronectin, a key adhesion
protein found in the blood and in the interstitial ECM, functions as
a promiscuous GF-binding protein (3). Through its second hepa-
rin-binding domain (FN III12-14), ﬁbronectin binds GFs from the
PDGF/VEGF and FGF families and some GFs from the TGF-β
and neurotrophin families. Similarly, vitronectin has been shown to
bind several GFs, likely through its heparin-binding domain (5, 7).
Because the heparin-binding domains of ﬁbronectin and vitro-
nectin bind a wide range of GFs from different families, we hy-
pothesized that ﬁbrin(ogen) could also bind GFs through its
heparin-binding domain.
Results
Binding of GF to Fibrinogen. We ﬁrst tested the capacity of ﬁbrin-
ogen to bind GFs from different families. GFs from the PDGF/
VEGF, FGF, TGF-β, IGF (including IGFBPs), and neurotrophin
families were selected. Binding of ﬁbrinogen to absorbed GFs was
detected using an antibody against ﬁbrinogen (Fig. 1A). Setting 1
as the highest signal possible, a signal signiﬁcantly greater than 0.1
was considered to indicate relevant binding. From the PDGF
family, VEGF-B, PDGF-AB, PDGF-BB, PDGF-DD, placenta
growth factor (PlGF)-2 and PlGF-3 showed binding to ﬁbrinogen,
whereas VEGF-A165, VEGF-A121, VEGF-C, PDGF-AA,
PDGF-CC, and PlGF-1 did not show relevant binding. From the
FGF family, FGF-2, FGF-5, and FGF-7 showed binding to ﬁ-
brinogen, whereas FGF-1, FGF-4, FGF-6, FGF-8, FGF-9, FGF-10,
and FGF-18 did not show strong binding. From the TGF-β su-
perfamily, TGF-β1, TGF-β2, BMP-2, and BMP-2/7 heterodimer
showed binding to ﬁbrinogen, but TGF-β3 and BMP-7 did not.
None of the IGFs were able to bind ﬁbrinogen directly, although
IGFBP-5 demonstrated binding. The neurotrophins neurotrophin-3
(NT-3) and BDNF showed binding to ﬁbrinogen, whereas nerve
growth factor (NGF) did not. In addition, EGF, heparin-binding
EGF (HB-EGF), and BSA (as a non-GF control) did not show
any binding to ﬁbrinogen.
Release of GF from Fibrin Matrix. We then tested whether a ﬁbrin
matrix (clot) could sequester the GFs that showed binding to ﬁ-
brinogen, considering theGFsVEGF-A121,VEGF-A165, PDGF-BB,
PlGF-1, PlGF-2, FGF-2, IGF-I, IGFBP-5, TGF-β1, BMP-2, BDNF,
and NGF as examples. Fibrinogen solutions containing GF were
polymerized to form ﬁbrin matrix using thrombin and factor
XIII. The resulting matrix was then incubated in an excess of
physiological buffer that was changed each day, and GF release
from the matrix was monitored by ELISA (Fig. 1B and Fig. S1). As
expected, the GFs that did not show strong binding to ﬁbrinogen—
VEGF-A165, VEGF-A121, PlGF-1, IGF1, and NGF—were
quickly released from the ﬁbrin matrix (>85% released after 1 d)
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(Fig. S1). In contrast, the several GFs that showed binding to
ﬁbrinogen—PlGF-2, FGF-2, BMP-2, TGF-β1, IGFBP-5, and
BDNF—showed retention within ﬁbrin matrix (Fig. 1B). Only
PDGF-BB did not exhibit strong retention (>80% released after
1 d). Interestingly, PlGF-2 and FGF-2 showed very strong reten-
tion within the ﬁbrin matrix, with only 12.3% and 32.5% released
after 7 d, respectively.
To ensure that the apparent slow release of FGF-2 and PlGF-2
was not related to an issue with their detection, the matrices were
digested after 7 d by plasmin to release ﬁbrin-bound GFs. After
digestion, 68.9% of FGF-2 and 85.6% of PlGF-2 were still de-
tected (Fig. 1C), conﬁrming mass balance and thus the very strong
interaction of these GFs with ﬁbrin.
Binding of GF to the Heparin-Binding Domain of Fibrin(ogen). Be-
cause the heparin-binding domains of ﬁbronectin and vitronectin
bind GFs (3, 7), we hypothesized that the heparin-binding do-
main of ﬁbrin(ogen) could bind GFs as well. We recombinantly
produced the heparin-binding domain of ﬁbrin(ogen) (15), lo-
cated at the N terminus of the ﬁbrin(ogen) β chain (Fg β). The
fragment, mimicking the situation in ﬁbrin, starts just after the
cleavage site of thrombin (Fg β15–66). Because the heparin-
binding domain of ﬁbrin(ogen) is naturally displayed as a dimer
(15), the fragment was dimerized at the cysteine residue at po-
sition 65 (Fg β15–66(2)) (Fig. 2 A and B). Moreover, for detection
purposes, a 6X His tag at the C terminus was added. Binding of
the ﬁbrinogen fragment to the absorbed GFs from the different
families was detected using an antibody against the tag. The GFs
that showed binding to ﬁbrin(ogen)—PlGF-2, PDGF-BB,
PDGF-DD, FGF-2, TGF-β1, TGF-β2, BMP-2, IGFBP-5, NT-3,
and BDNF—showed binding to Fg β15–66(2) (Fig. 2C). GFs that
did not show strong binding to ﬁbrinogen—VEGF-A165,
VEGF-A121, PlGF-1, PDGF-CC, FGF-1, FGF-6, FGF-10,
TGF-β3, BMP-7, IGF-I, IGF-II, IGFBP-1, IGFBP-3, NGF, and
EGF—did not show relevant binding to Fg β15–66(2) (Fig. 2C).
Although FGF-7 and TGF-β2 showed relevant binding to ﬁ-
brinogen, their binding to Fg β15–66(2) was more modest.
To further examine the interaction of GFs with the heparin-
binding domain of ﬁbrin(ogen), we generated four other mono-
meric variants (Fig. 2B) and tested them with GFs representative
of each family (PlGF-1, PlGF-2, FGF-1, FGF-2, TGF-β1, TGF-
β3, IGFBP-4, and IGFBP-5) (Fig. 2D). A fragment mimicking the
situation in ﬁbrinogen contained the ﬁbrinopeptide (Fg β1–66);
two other fragments were truncations from the N terminus (Fg
β31–66 and Fg β48–66). In addition, we generated a variant in
which all lysine and arginine residues were substituted with serine
(Fg β15–66*S). We found that dimerization of Fg β15–66 im-
proved the binding of GFs (Fig. S2). Fg β1–66 showed similar
binding to GFs as Fg β15–66 (Fig. 2D). Moreover, Fg β31–66
displayed a signiﬁcant GF-binding activity, whereas Fg β48–66
and Fg β15–66*S did not (Fig. 2D).
Speciﬁcity of binding was then addressed by competing the
binding of GFs to absorbed ﬁbrinogen with soluble Fg β15–66(2).
Binding of the GFs (PlGF-2, FGF-2, TGF-β1, and IGFBP-5) to
absorbed ﬁbrinogen was detected using an antibody against the
GF (Fig. S3). For all of the GFs tested, we could observe a dose-
dependent competition. IC50 values of 6.6 nM for PlGF-2, 19.1 nM
for FGF-2, 19.6 nM for TGF-β1, and 18.8 nM for IGFBP-5.
Afﬁnity of GF for Fg β15–66(2). Surface plasmon resonance (SPR)
was used to estimate the afﬁnity toward ﬁbrinogen of selected
GFs from the foregoing list. SPR chips were functionalized with
Fg β15–66(2), and GFs chosen from each family (i.e., PlGF-2,
TGF-β1, FGF-2, and IGFBP-5) were analyzed. The curves ob-
tained for the speciﬁc binding signal to Fg β15–66(2) were ﬁtted
with Langmuir binding kinetics, and dissociation constants (KD),
and rate constants (kon and koff) were calculated from the ﬁts
(Fig. S4 A and B). KD values were 1.9 nM for PlGF-2, 56.5 nM
for TGF-β1, 53.0 nM for FGF-2, and 19.6 nM for IGFBP-5.
Inﬂuence of Heparin on Binding of GF to Fg β15–66(2). Because both
Fg β15–66(2) and heparin-binding GFs bind heparin, we explored
the potential role of heparin in modulating their interaction. The
GFsVEGF-A165, PlGF-2, PDGF-BB, PDGF-DD, FGF-7, FGF-10,
TGF-β1, TGF-β2, BMP-2, IGFBP-3, IGFBP-5, NT-3, and BDNF
were adsorbed on an ELISA plate, followed by incubation with Fg
β15–66(2) with or without heparin in excess (20-fold molar excess
relative to Fg β15–66(2)) (Fig. S5A). With heparin in excess,
binding to theGFwas decreased for VEGF-A165, FGF-2, FGF-7,
FGF-10, TGF-β1, TGF-β2, IGFBP-3, IGFBP-5, and NT-3; in-
creased slightly for PDGF-BB, BMP-2, and BDNF; and did not
differ for PlGF-2 and PDGF-DD. In addition, a competition assay
was performed using a range of heparin concentrations (10- to
10,000-fold molar excess relative to Fg β15–66(2)) with selected
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Fig. 1. GF binding to ﬁbrin(ogen). (A) ELISA plates were coated with GFs or
BSA and further incubated with ﬁbrinogen. Bound ﬁbrinogen was detected
using an antibody (n ≥ 4; mean ± SEM). A signal signiﬁcantly greater than
0.1 (gray box) was considered representative of a speciﬁc binding. *P < 0.05;
**P < 0.01; ***P < 0.001, one-sample Student t test. Binding was highly
promiscuous; unique interactions are shown in gray, and previously known
interactions are shown in black. (B and C) GF retention in ﬁbrin matrix. Fibrin
matrices were produced in the presence of a GF and further incubated in
eight volumes of physiological buffer for 7 d. The buffer was changed each
day, and released GFs were quantiﬁed for each day. (B) Graph showing the
cumulative release of GFs over 7 d (n ≥ 3; mean ± SEM). (C) After 7 d,
fractions of FGF-2 and PlGF-2 remaining in the matrices were quantiﬁed
after the gels were digested by plasmin (n = 3; mean ± SEM).
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GFs from each family: PlGF-2, TGF-β1, FGF-2, and IGFBP-5
(Fig. S5B). IC50 values were 9.4 μMfor PlGF-2, 8.4 μMfor FGF-2,
0.7 μM for TGF-β1, and 2.0 μM for IGFBP-5.
Inﬂuence of Fg β15–66(2) on GF Activity. We explored the potential
modulation of the activity of GFs in the presence of Fg β15–66(2)
using a cell proliferation assay (Fig. S6). Proliferation of human
endothelial cells was induced with solution of GFs (VEGF-A165,
VEGF-A121, PlGF-1, PlGF-2, or FGF-2) containing ﬁbrinogen
or Fg β15–66(2) in excess (≥100-fold molar excess relative to
GFs). Cells stimulated with GFs were signiﬁcantly increased in
number, but no signiﬁcant differences were found between cells
treated with GFs only and cells treated with GFs plus ﬁbrinogen
or Fg β15–66(2), suggesting that the binding of GFs to ﬁbrin
(ogen) does not modulate their activity in vitro.
Incorporation of Fg β15–66(2) into a Fibrin-Mimetic Matrix to Treat
Chronic Wounds. Based on the promiscuous but high-afﬁnity in-
teractions of GFs with ﬁbrin(ogen) and their subsequent retention
in ﬁbrin matrices, GF binding may be an important physiological
function of ﬁbrin, and these interactions may possibly play an
important role during tissue repair. To investigate this function, we
incorporated Fg β15–66(2) into a multifunctional poly(ethylene
glycol) (PEG) matrix designed to mimic ﬁbrin’s main functions.
The ﬁbrin-mimetic matrix backbone comprised two eight-arm
PEG peptide conjugates (at a concentration of 1.75%) cross-
linkable by the ﬁbrin stabilizing factor, transglutaminase factor
XIIIa (16, 17). PEG was conjugated with a peptide containing
a factor XIIIa substrate sequence derived from α2-plasmin in-
hibitor (α2PI1–8, NQEQVSPL) (18) or with a lysine donor peptide
containing a substrate sequence for matrix metalloproteases
(MMPs) and plasmin (VPMSMRGG) (19), allowing degradation
of the matrix in situ. During polymerization by factor XIIIa, the
matrix was further functionalized with a peptide containing a
promiscuous integrin-binding sequence (α2PI1–8-RGDSPG; 40 μM)
that promote cell adhesion and with a cross-linkable version of Fg
β15–66(2) (α2PI1–8-Fg β15–66(2); 10 μM), to allow binding of GFs
(Fig. 3A). As examples of GFs, we chose FGF-2 and PlGF-2,
because these GFs showed the strongest interactions with ﬁbrin
(ogen) and Fg β15–66(2), and because they are known to promote
wound healing (20, 21). The ﬁbrin matrix (Fig. 1B) and the
ﬁbrin-mimetic matrix functionalized with Fg β15–66(2) were
both able to sequester FGF-2 and PlGF-2, and after degradation
by plasmin, GFs could be completely released (Figs. 1C and 3B).
We then evaluated the synthetic matrix in vivo. We used the
db/db mouse, which is a genetic mouse model of diabetes that pro-
vides a well-established and clinically relevant experimental system
of impaired wound healing (22, 23). We treated full-thickness back
skin wounds of these mice with GFs (FGF-2 and PlGF-2, 200 ng of
each) delivered by a ﬁbrin matrix or by the ﬁbrin-mimetic matrix.
Twelve groups were tested: no treatment (no matrix); ﬁbrin only;
ﬁbrin containing FGF-2 and/or PlGF-2; PEG matrix only, PEG
matrix containing FGF-2 and PlGF-2, PEG matrix functionalized
with α2PI1–8-Fg β15–66(2), PEGmatrix functionalizedwith α2PI1–8-
Fg β15–66(2) containing FGF-2 and/or PlGF-2, and PEG matrix
functionalized with α2PI1–8-Fg β15–66(2) containing FGF-2 and
PlGF-2 without the integrin-binding sequence (RGD). Wounds
were analyzed and compared with no treatment after 10 d, con-
sidering thatwounds are normally fully closed after 15 dwhen treated
only with ﬁbrinmatrix (9). The wounds treatedwithmatrices that did
not contain GFs or Fg β15–66(2) did not differ signiﬁcantly from
wounds without treatment, in either the amount of granulation tissue
or extent of wound closure (the latter indicated by reepithelializa-
tion). With the ﬁbrin-mimetic matrix lacking Fg β15–66(2), dual de-
livery of FGF-2 and PlGF-2 resulted in only slightly improved wound
healing (Fig. 3 D and E). In contrast, delivering FGF-2 or PlGF-2
with the ﬁbrin-mimetic matrix functionalized with Fg β15–66(2) or
with the ﬁbrin matrix led to faster wound closure and signiﬁcantly
more granulation tissue (Fig. 3C–E). In addition, the delivery of both
FGF-2 and PlGF-2 by ﬁbrin or by the ﬁbrin-mimetic matrix func-
tionalized with Fg β15–66(2) led to signiﬁcantly faster wound closure
and increased development of granulation tissue (Fig. 3 C–E).
Because angiogenesis is a crucial step in sustaining newly
formed granulation tissue within the wound bed (10), we focused
on the extent to which angiogenesis differed among the treat-
ments. We detected the standard marker for blood vessels, CD31,
which is highly expressed by endothelial cells, although other cells
within the granulation tissue, including platelets and some other
immune cells, also express CD31 to some extent. In addition, we
detected desmin as a speciﬁc marker for smooth muscle cells
surrounding blood vessels. Immunohistological analysis for CD31
and desmin revealed that angiogenesis within the granulation
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tissues was much more pronounced when GFs were delivered
within ﬁbrin or the ﬁbrin-mimetic matrix functionalized with Fg
β15–66(2) (Fig. 4 A–C and Fig. S7). Smooth muscle (i.e., desmin-
positive) cells were observed to be generally colocalized with
endothelial (i.e., CD31+) cells (Fig. 4 A–C and Fig. S7 A and B),
conﬁrming that the structures observed were blood vessels and
suggesting that they were mature and stable at day 10.
Discussion
During morphogenesis and tissue healing, interactions of GFs
with the ECM are critical to regulation of their partitioning, local
diffusion, and signaling (1, 2, 9). In tissue healing, the provisional
ﬁbrin matrix is supposed to act as a GF reservoir (11), and ﬁbrin
(ogen) has been shown to bind to FGF-2 (14, 24), VEGF-A165
(13), and IGFBP-3 (12). Given our recent ﬁnding that the second
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Fig. 3. Fibrin-mimetic matrix. (A) The matrix comprises two eight-arm PEG-peptide conjugates (PEG-plasmin/MMP-K and PEG-α2PI1–8), a cell-adhesion peptide
(α2PI1–8-RGD), α2PI1–8-Fg β15–66(2), and GF(s). Through the transglutaminase factor XIIIa, peptide bounds are formed between the ﬁrst glutamine in α2PI1–8
(NQEQVSPL) and the lysine in PEG-plasmin/MMP-K, resulting in simultaneous cross-linking and functionalization of the matrix. (B) Retention of ﬁbrin-binding
GFs in ﬁbrin-mimetic matrix functionalized with α2PI1–8-Fg β15–66(2). The graph shows the cumulative release of GFs and α2PI1–8-Fg β15–66(2) over 7 d.
Fractions of GFs remaining in the matrices were quantiﬁed after the matrix was digested by plasmin (n = 3; mean ± SEM). (C–E) Delivering GFs within the
ﬁbrin-mimetic matrix functionalized with α2PI1–8-Fg β15–66(2) enhances skin wound healing in diabetic mice. Full-thickness back skin wounds were treated
with FGF-2 and/or PlGF-2 (200 ng of each per wound). Twelve groups were tested: no treatment (no matrix); ﬁbrin only or ﬁbrin containing FGF-2 and/or PlGF-2;
PEG matrix (with plasmin/MMP-sensitive and RGD peptides) or PEG matrix containing FGF-2 and PlGF-2; PEG matrix functionalized with α2PI1–8-Fg β15–66(2) or
PEG matrix functionalized with α2PI1–8-Fg β15–66(2) containing FGF-2 and/or PlGF-2; and PEG matrix functionalized with α2PI1–8-Fg β15–66(2) containing FGF-2 and
PlGF-2 but without RGD (−RGD). (C and D) After 10 d, wound closure and granulation tissue area were evaluated by histological analysis. All points are mean ±
SEM (n = 8 per matrix). Statistical comparisons were done using ANOVA with Tukey’s test. *P < 0.05; **P < 0.01. (E) Representative histology (H&E staining).
Black arrows indicate wound edges; red arrows indicate tips of epithelium tongue. The granulation tissue, stained in pink-violet, is characterized by a large
number of cells (granulocytes) with nuclei that stain in dark violet. Muscle under the wounds is stained in red. Fat tissue appears as transparent bubbles. (Scale
bar: 1 mm.) To the right are higher-magniﬁcation (5×) views of the granulation tissue.
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heparin-binding domain of ﬁbronectin acts as a promiscuous GF-
binding domain (3), we explored the possibility that ﬁbrin(ogen)
could also bind GFs very promiscuously through its heparin-
binding domain.
We found that many GFs from the PDGF/VEGF family, FGF
family, and TGF-β superfamily, as well as some GFs from the
neurotrophin family, bind ﬁbrinogen (Fig. 1A). To graphically
illustrate the numerousﬁndings from this investigation, Fig. 1A
shows the interactions reported herein in gray and previously
known interactions with ﬁbrinogen in black. Importantly, the
lack of signal shown by some GFs likely was not related to poor
coating efﬁciency on the ELISA plate surface; for example, we
previously reported no difference in coating efﬁciency between
VEGF-A165 and VEGF-A121 or among the PlGFs (3).
We then examined whether GFs were also able to bind ﬁbrin
and, if so, whether the binding was sufﬁciently strong for the
sequestering of GFs into the matrix. As expected, the GFs that
did not bind ﬁbrinogen were quickly released from ﬁbrin matrix,
whereas the GFs that did show binding were retained (Fig. 1B
and Fig. S1). Interestingly, the strength of retention varied
among the GFs. FGF-2 and PlGF-2 released very slowly, show-
ing retention of ∼70% and ∼85% after 7 d, respectively. This
strong retention correlated with the earlier binding experiment,
with FGF-2 and PlGF-2 showing the highest signals for binding
to ﬁbrinogen. BDNF, TGF-β1, BMP-2, and IGFBP-5 showed
high binding to ﬁbrinogen, as well as retention in ﬁbrin matrix.
Interestingly, PDGF-BB showed binding to ﬁbrinogen, but its
release from the matrix was relatively rapid (∼80% after 1 d).
This difference may be explained by the fact that the ELISA
used for the screening of GF binding to ﬁbrinogen was limited to
revealing interactions occurring in the solid phase. Thus, it is
possible that some interactions were slightly overevaluated or
underevaluated compared with those occurring in the physio-
logically relevant release assay (Fig. 1B).
We then examined whether the heparin-binding domain of
ﬁbrin(ogen) (Fig. 2 A and B) could act as a GF-binding domain.
Among the GFs tested, all GFs that showed relevant binding to
ﬁbrin(ogen) also showed binding to Fg β15–66(2) (Fig. 2C). Only
FGF-7 and TGF-β2 showed more modest binding to the ﬁbrin
fragment. From a structure-function standpoint, we found that
mimicking the situation within ﬁbrin(ogen) through the dimer-
ization of Fg β15–66 improves GF binding (Fig. S2). The pres-
ence of the ﬁbrinopeptide (i.e., in Fg β1–66) did not change GF
binding, suggesting that ﬁbrin and ﬁbrinogen have similar afﬁnity
for GFs (Fig. 2D). In addition, because positively charged amino
acids within the second heparin-binding domain of ﬁbronectin
are known to be involved in the binding of GFs (3), we generated a
variant in which all lysine and arginine residues were substituted
with serine (Fg β15–66*S). As expected, we found that lysines and
arginines within Fg β15–66 are determinant for GF binding, given
that their substitution abolished the binding of GFs (Fig. 2D).
Moreover, the sequence PAPPPISGGGYRARPAK (Fg β31–47)
is critical for GF binding, considering that Fg β31–66 showed
signiﬁcant GF-binding activity, whereas Fg β48–66 did not
(Fig. 2D).
We further tested if Fg β15–66(2) could inhibit the binding of
GFs to absorbed ﬁbrinogen, testing one GF per family. IC50
values were in the nM range, suggesting that the main GF-
binding site within ﬁbrin(ogen) is its heparin-binding domain
(Fig. S3). Nevertheless, considering the size of ﬁbrin(ogen) and
its complexity, it is possible that other GF-binding sites are
present as well.
We estimated the afﬁnity of GFs to Fg β15–66(2) using SPR,
measuring the afﬁnity of one GF per family. Remarkably, all GFs
tested had equilibrium dissociation constants in the nM range,
indicating that the interactions are very strong (Fig. S4). Indeed,
the afﬁnities reported here are in the same range as those that
have been reported for the binding of FGF-2 to ﬁbrinogen (25).
Similar to the binding to ﬁbronectin (3), this broad yet high af-
ﬁnity is somewhat perplexing; very high afﬁnities would be
expected to be highly speciﬁc, but in this case the high-afﬁnity
interaction also appears to be promiscuous. Interestingly, most
of the GFs that have been shown to bind ﬁbronectin (3) also bind
ﬁbrinogen, suggesting a similar binding mechanism. Only PDGF-
AA, FGF-18, and BMP-7 showed speciﬁc binding to ﬁbronectin,
but not to ﬁbrinogen. Although the afﬁnity values obtained with
SPR are on the same order of magnitude, the afﬁnity of GFs for
ﬁbronectin seems to be higher, except for PlGF-2, which displays
a similar afﬁnity for both ECM proteins (Fig. S4 B and C).
Interestingly, all GFs that were shown to bind ﬁbrin(ogen)
through Fg β15–66(2) can bind or are predicted to bind heparin.
However, some known heparin-binding GFs, including PDGF-
AA, FGF-1, FGF-6, FGF-18, IGF-II, BMP-7, TGF-β3, and NGF
(26), did not show binding to ﬁbrinogen. Thus, the presence of
a heparin-binding domain within the GFs seems to be necessary,
but not sufﬁcient, to provide binding to Fg β15–66(2). We and
others have shown enhanced binding of GFs to ﬁbronectin in the
presence of heparin, although heparin is not the linker between
the two molecules (3, 4, 27). It has been suggested that heparin
and heparan sulfate can change the conformation of ﬁbronectin
and increase its afﬁnity for GFs (4, 27); however, in the case of
GF–Fg β15–66(2) interaction, heparin did not increase GF-
binding ability, but rather decreased it (Fig. S5). Thus, the mecha-
nism of GF binding to ﬁbronectin, ﬁbrinogen, or heparan sulfate
proteoglycans appears to be complex, and may be resolved by
further crystallographic studies of each complex.
The binding of ﬁbrinogen and Fg β15–66(2) to GFs could in-
ﬂuence the activity of GF with their respective receptors. For
example, synergistic signaling with integrins could occur, as is the
case with ﬁbronectin (9), or the binding could inhibit interaction
with the receptor and reduce GF activity. To determine whether
the binding has an effect on GF signaling, we induced endo-
thelial cell proliferation with ﬁbrin(ogen)-binding GFs with or
without Fg β15–66(2) or ﬁbrinogen. Fibrinogen and Fg β15–66(2)
slightly increased the proliferative effect of the GFs tested, but
did not promote any synergy (Fig. S6), as has been reported for
ﬁbronectin with VEGF-A165 (9). Based on these results, we can
conclude that ﬁbrin(ogen) binds but does not modulate the ac-
tivity of these GFs in vitro.
The binding of GF to ﬁbrin(ogen) may be very important for
wound healing processes. Platelets and macrophages within the
ﬁbrinous matrix provide a continuous source of GFs necessary to
stimulate angiogenesis and other healing processes. By binding
the newly secreted GFs, ﬁbrin could act as a GF reservoir while
also creating biochemical gradients required for appropriate cell
inﬁltration into the lesion. In addition, other ECM proteins
present in the ﬁbrin clot, such as ﬁbronectin and vitronectin, bind
GFs and act as bridging molecules between cells and ﬁbrin by
binding to the integrins on endothelial cells, smooth muscle cells,
and other cell types (28). Moreover, GFs critical for angiogenesis
during wound healing, such as FGF-2, bind ﬁbrin(ogen) and ﬁ-
bronectin (3).
To evaluate the GF-binding function of ﬁbrin, we implanted Fg
β15–66(2) into a synthetic PEG matrix mimicking ﬁbrin’s main
characteristics (Fig. 3A). As such, the PEG matrix was designed
to contain a promiscuous integrin-binding sequence to provide
adhesion to multiple cell types, an optimized MMP and plasmin
degradation-sensitive sequence (19) to allow rapid degradation of
the matrix, and Fg β15–66(2) as a GF-binding domain. Further-
more, the biosynthetic matrix can be polymerized in situ using the
ﬁbrin-stabilizing factor, factor XIIIa. As expected, similar to ﬁbrin
matrix, the ﬁbrin-mimetic matrix functionalized with α2PI1–8-Fg
β15–66(2) was able to sequester ﬁbrin(ogen)-binding GFs, such as
FGF-2 and PlGF-2 (Fig. 3B). Then, because preclinical evalua-
tions of GFs for chronic skin wound healing are generally per-
formed in rodents, most commonly in db/db diabetic mice (9), we
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used that model to investigate wound healing by FGF-2 and
PlGF-2 delivered by ﬁbrin or by the ﬁbrin-mimetic matrix. We
chose FGF-2 and PlGF-2 because they strongly bind Fg β15–66(2),
and because both of these GFs are known to improve wound
healing (20, 21). Using this gain-of-function model, we sought to
explore the extent to which inclusion of Fg β15–66(2) into the
matrix could recapitulate the function of ﬁbrin in vivo. We found
that effective sequestration and presentation of FGF-2 and/or
PlGF-2 by α2PI1–8-Fg β15–66(2) could improve neovessel forma-
tion that sustains the newly formed granulation tissue (Fig. 4 A–
C and Fig. S7). Granulation tissue morphogenesis translated to
improved morphogenesis at the level of the dermal epithelium,
as reﬂected by faster wound reepithelialization and closure (Fig. 3
C–E). As such, the ﬁbrin-mimetic matrix could fully recapitulate
ﬁbrin’s efﬁcacy in promoting wound healing by binding FGF-2
and PlGF-2.
To determine whether the RGD sequence is critical, and
to simplify the ﬁbrin-mimetic matrix, we removed the integrin-
binding peptide in the matrix that demonstrated the best healing.
Surprisingly, the delivery of FGF-2 and PlGF-2 with or without
RGD resulted in very similar healing (Fig. 3 D and E), with only
slightly lower angiogenesis without RGD (Fig. 4C), although the
difference was not statistically signiﬁcant. Thus, the RGD se-
quence could be removed when designing ﬁbrin-mimetic matri-
ces for skin wound healing. Nevertheless, this ﬁnding does not
mean that ligation of the appropriate intergins cannot enhance
skin repair. Indeed, although promiscuous, RGD cannot engage
critical integrins for wound healing, such as integrin α5β1 (9).
Additional functionalization of the ﬁbrin-mimetic matrix with
integrin-speciﬁc ﬁbronectin fragments possibly could further
enhance wound healing (9).
Clinically available ﬁbrin is widely used as a sealant and has
the potential for use as an efﬁcient GF-delivery system for
multiple purposes (29). Of special interest, we show here that an
impressive number of GFs strongly bind this material. The sub-
stitution of ﬁbrin with a synthetic matrix would have numerous
beneﬁts, however. The tailorability of synthetic materials allows
greater control of cell–matrix interactions, such as the matrix
degradation rate and matrix stiffness, both of which are critical in
driving tissue repair or regeneration (29). Thus, this ﬂexibility can
ﬁll unmet needs in regenerative medicine by providing a speciﬁc
and more controlled environment. Moreover, unlike ﬁbrin, which
is puriﬁed from human plasma, a synthetic ﬁbrin-mimetic matrix
beneﬁts strongly from a more straightforward regulatory path
associated with chemical synthesis rather than human sourcing.
In conclusion, we found that ﬁbrin(ogen) promiscuously binds
GFs from the PDGF, FGF, TGF-β, and neurotrophin families
through its heparin-binding domain. Overall, 15 unique binding
interactions were established, and all of the GFs evaluated dis-
played KD values in the nM range. Therefore, ﬁbrin(ogen) could
play a broad role in GF binding in the ﬁbrin clot. Finally, by en-
gineering a ﬁbrin-mimetic matrix displaying the GF-binding prop-
erty of ﬁbrin, we have demonstrated that the binding of GFs to
ﬁbrin is critical for wound healing. Furthermore, we have shown
that reproduction of the GF–ECM interaction within nonhuman-
derived biomaterials could be clinically useful. The synthetic ﬁbrin-
mimetic matrix could substitute ﬁbrin for regenerative medicine
applications, and, moreover, Fg β15–66(2) could be incorporated
into other biomaterials to support GF presentation.
Materials and Methods
Detailed information is provided in SI Materials and Methods. GF binding
to ﬁbrin(ogen) and Fg β15–66(2) by ELISA and SPR. Synthesis of the ﬁbrin-
mimetic matrix. Wound healing model and analyses of wound tissue
sections.
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